AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19152909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation + 10 mg oral metoclopramide before the procedure
Number of subjects: 150
Study 19152909 — intervention group
Group type: EXPERIMENTAL
Intervention: Citramag + senna bowel-purgative regimen the evening before CE
Number of subjects: 150
Study 19152909 — intervention group
Group type: EXPERIMENTAL
Intervention: Citramag + senna + 10 mg metoclopramide before the procedure
Number of subjects: 150
Study 15891596 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic therapy with cisapride (10 mg t.i.d.) after 4 weeks
Number of subjects: 17
Study 15891596 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions (before treatment)
Number of subjects: 17
Study 15891596 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17
Study 11568201 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 86
Study 11568201 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 86
Study 9604732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium auro-thiomalate
Number of subjects: 40
Study 8111937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 3292844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-vaginal suppositories containing S. nigrescens maceration
Number of subjects: 50
Study 3292844 — intervention group
Group type: COMPARATOR
Intervention: Nystatin suppositories
Number of subjects: 50
Study 12472200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0
Study 12472200 — intervention group
Group type: COMPARATOR
Intervention: Uremic patients
Number of subjects: 0
Study 12472200 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical analysis
Number of subjects: 0
Study 29995693 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exercise (CEX) including 2 aerobic and 9 resistance exercises performed alternately in circuit order for 40 minutes at 60-70% heart rate reserve using body mass or fixed loads.
Number of subjects: 16
Study 29995693 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CONT) sessions.
Number of subjects: 16
Study 26189007 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg single dose
Number of subjects: 24
Study 24135979 — intervention group
Group type: EXPERIMENTAL
Intervention: F+GOS (galacto-oligosaccharide)
Number of subjects: 27
Study 24135979 — intervention group
Group type: EXPERIMENTAL
Intervention: F+HMO (human milk oligosaccharides)
Number of subjects: 27
Study 24135979 — intervention group
Group type: EXPERIMENTAL
Intervention: H+H (mother's own milk fortified with concentrated donor human milk product)
Number of subjects: 27
Study 24135979 — intervention group
Group type: COMPARATOR
Intervention: H+B (mother's own milk fortified with bovine powdered fortifier)
Number of subjects: 27
Study 24135979 — intervention group
Group type: EXPERIMENTAL
Intervention: F+GOS
Number of subjects: 27
Study 24135979 — intervention group
Group type: EXPERIMENTAL
Intervention: H+H
Number of subjects: 27
Study 22863133 — intervention group
Group type: EXPERIMENTAL
Intervention: n-HAP paste (Renamel AfterBleach, Sangi Co., Ltd., Tokyo, Japan)
Number of subjects: 42
Study 22863133 — intervention group
Group type: COMPARATOR
Intervention: zero-HAP (placebo)
Number of subjects: 42
Study 19692142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.6mg/m(2)) plus Pemetrexed (500mg/m(2)) on day 1 (Arm A)
Number of subjects: 155
Study 19692142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500mg/m(2)) on day 1 (Arm B)
Number of subjects: 155
Study 19692142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.6mg/m(2)) on days 1 and 8 (Arm C)
Number of subjects: 155
Study 18608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane35 (35 microg ethinyl estradiol plus 2 mg cyproterone acetate)
Number of subjects: 60
Study 18608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane35
Number of subjects: 60
Study 18608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study 18608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane35 and Diane35/metformin
Number of subjects: 60
Study 18608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane35/metformin
Number of subjects: 60
Study 15650667 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate anterior stabilization plus rehabilitation
Number of subjects: 40
Study 15650667 — intervention group
Group type: COMPARATOR
Intervention: Immobilization followed by rehabilitation
Number of subjects: 40
Study 12460869 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine (3 mg IC)
Number of subjects: 46
Study 12460869 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil (10 mg IC)
Number of subjects: 46
Study 12460869 — intervention group
Group type: COMPARATOR
Intervention: Revascularization
Number of subjects: 46
Study 10509773 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (10 microg/d for 3 months)
Number of subjects: 191
Study 10509773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 191
Study 8738770 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg, 15 mg/kg, or 30 mg/kg administered once daily for 7 days
Number of subjects: 59
Study 2016451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp treadmill protocols
Number of subjects: 41
Study 2016451 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer protocols
Number of subjects: 41
Study 2016451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp treadmill tests
Number of subjects: 41
Study 2016451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp cycle ergometer tests
Number of subjects: 41
Study 2016451 — intervention group
Group type: COMPARATOR
Intervention: Bruce treadmill tests
Number of subjects: 41
Study 2016451 — intervention group
Group type: COMPARATOR
Intervention: 50 W/stage cycle ergometer tests
Number of subjects: 41
Study 7102537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg four times a day)
Number of subjects: 12
Study 7102537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7102537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12
Study 31811686 — intervention group
Group type: EXPERIMENTAL
Intervention: Overheard praise for a classmate being smart (experimental condition)
Number of subjects: 200
Study 31811686 — intervention group
Group type: COMPARATOR
Intervention: Non-social information (control condition)
Number of subjects: 200
Study 30644008 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA; Gleolan®)
Number of subjects: 0
Study 30644008 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgery
Number of subjects: 0
Study 30321275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain orange maize (WGOM) muffins
Number of subjects: 9
Study 30321275 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined orange maize (ROM) muffins
Number of subjects: 9
Study 30321275 — intervention group
Group type: COMPARATOR
Intervention: Refined white maize (RWM) muffins
Number of subjects: 9
Study 27013067 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-size trephine
Number of subjects: 118
Study 27013067 — intervention group
Group type: COMPARATOR
Intervention: Oversize trephine
Number of subjects: 118
Study 25136444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 52
Study 25136444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 52
Study 22290969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cethromycin
Number of subjects: 0
Study 22290969 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study 19641491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 100
Study 19641491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17123633 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature search task
Number of subjects: 40
Study 17123633 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunction search task
Number of subjects: 40
Study 17123633 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 40
Study 17123633 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 40
Study 15898977 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with depigmented glutaraldehyde-polymerized extracts (Group-A)
Number of subjects: 53
Study 15898977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group-C)
Number of subjects: 53
Study 12126265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5-5 mg daily (n = 81)
Number of subjects: 168
Study 12126265 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg daily (n = 87)
Number of subjects: 168
Study 12126265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 168
Study 12126265 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 168
Study 9508173 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL‐2 9 x 10(6) IU/m2 daily by continuous intravenous infusion for 4 days, followed by IL‐2 1.6 x 10(6) IU/m2 daily for 10 days
Number of subjects: 21
Study 7697845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (1000 mg/d)
Number of subjects: 216
Study 7697845 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 216
Study 2664696 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature biofeedback with daily home practice of relaxation-mental imagery techniques
Number of subjects: 31
Study 2664696 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo condition
Number of subjects: 31
Study 1071668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (200-400 mg, twice daily)
Number of subjects: 7
Study 30564892 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic immune risk score (dIRS) model
Number of subjects: 940
Study 30564892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic immune risk score (pIRS) model
Number of subjects: 940
Study 30564892 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of pIRS with clinical characteristics
Number of subjects: 940
Study 28334661 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 100
Study 28334661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25308399 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program in consultation skills for pediatric diabetes teams
Number of subjects: 0
Study 22968811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole and St John's wort for 8 days
Number of subjects: 0
Study 22968811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole after St John's wort induction
Number of subjects: 0
Study 22968811 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of both drugs
Number of subjects: 0
Study 21707136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 306
Study 21707136 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 306
Study 19166687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 153
Study 19166687 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 153
Study 17143135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner plus usual care
Number of subjects: 236
Study 17143135 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 236
Study 12918144 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 40
Study 12918144 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 40
Study 10834423 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 534
Study 10834423 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 534
Study 9210007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 26
Study 8216696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 to 75 mg)
Number of subjects: 29
Study 8216696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8216696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 29
Study 3549811 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% minoxidil
Number of subjects: 66
Study 3549811 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% minoxidil
Number of subjects: 66
Study 3549811 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil (1% and 5%)
Number of subjects: 66
Study 31269890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day for 12 weeks)
Number of subjects: 86
Study 31269890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 28586258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco counter-advertisements targeting smokers' brands
Number of subjects: 260
Study 28586258 — intervention group
Group type: COMPARATOR
Intervention: Tobacco counter-advertisements targeting other brands
Number of subjects: 260
Study 26922146 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-60mg/day)
Number of subjects: 1555
Study 26922146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1555
Study 26922146 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1555
Study 24393129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 78
Study 24393129 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 78
Study 22789665 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Journey Survey (PJS) method
Number of subjects: 92
Study 22789665 — intervention group
Group type: COMPARATOR
Intervention: Current Accreditation Survey (CAS) method
Number of subjects: 92
Study 19601782 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (1.5 mcg/Kg/w) plus RBV (>=10.6 mg/kg/d) for 24-48 or 48-72 weeks depending on genotype
Number of subjects: 100
Study 19601782 — intervention group
Group type: EXPERIMENTAL
Intervention: TMA assay for HCV‐RNA
Number of subjects: 100
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 2 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 4 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg to 2 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg to 4 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 2 mg to 4 mg
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs)
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital signs and ECG parameters
Number of subjects: 52
Study 17617285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematology and serum chemistry panels
Number of subjects: 52
Study 12736156 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (600 mg/wk for 3 weeks)
Number of subjects: 0
Study 11075768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of vitamin K orally
Number of subjects: 89
Study 11075768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8725470 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CO2/20.9% O2/balance N2 (hypercapnia trial)
Number of subjects: 8
Study 8725470 — intervention group
Group type: COMPARATOR
Intervention: Humidified room air (control trial)
Number of subjects: 8
Study 1358233 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (2.4 micrograms/kg/min)
Number of subjects: 0
Study 1358233 — intervention group
Group type: COMPARATOR
Intervention: Thymoxamine (80 mg)
Number of subjects: 0
Study 1358233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine co-administration with phenylephrine
Number of subjects: 0
Study 4009935 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture with Tokki pI 200 at 1 Hz during neuroleptic anesthesia
Number of subjects: 14
Study 4009935 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic anesthesia composed of droperidol, fentanyl, and nitrous oxide (70%) supplemented by a muscle relaxant
Number of subjects: 14
Study 3098804 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing dentifrice
Number of subjects: 0
Study 3098804 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice at 1100 ppm
Number of subjects: 0
Study 3098804 — intervention group
Group type: COMPARATOR
Intervention: Fluoride paste (commercial)
Number of subjects: 0
Study 31761964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study 31761964 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic instrumental variable analysis
Number of subjects: 0
Study 29641307 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation (SES)
Number of subjects: 24
Study 29641307 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 28349386 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 56
Study 26053169 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal paracentesis drainage (APD)
Number of subjects: 255
Study 26053169 — intervention group
Group type: COMPARATOR
Intervention: No abdominal paracentesis drainage (Control)
Number of subjects: 255
Study 23350812 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.2 mg
Number of subjects: 24
Study 23350812 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.5 mg
Number of subjects: 24
Study 23350812 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.8 mg
Number of subjects: 24
Study 23350812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21080144 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 180
Study 21080144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 180
Study 21080144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and fluoxetine
Number of subjects: 180
Study 21080144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 18071020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) at 40 cm H(2)O
Number of subjects: 17
Study 18071020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E)
Number of subjects: 17
Study 16584394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction (CIFN 27->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) with ribavirin 800 mg/day
Number of subjects: 103
Study 16584394 — intervention group
Group type: COMPARATOR
Intervention: Low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks) with ribavirin 800 mg/day
Number of subjects: 103
Study 16584394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction
Number of subjects: 103
Study 16584394 — intervention group
Group type: COMPARATOR
Intervention: Low-dose treatment
Number of subjects: 103
Study 16584394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 103
Study 12827364 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion into the anterior tibial muscle (Mu)
Number of subjects: 14
Study 12827364 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion into the muscle including manipulation of the needle (DeQi)
Number of subjects: 14
Study 12827364 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial insertion (SF)
Number of subjects: 14
Study 12827364 — intervention group
Group type: COMPARATOR
Intervention: Control (no needle stimulation)
Number of subjects: 14
Study 11053512 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 94
Study 11053512 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 94
Study 9357879 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural epinephrine (100 microg in saline)
Number of subjects: 15
Study 9357879 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (8 microg/kg in saline)
Number of subjects: 15
Study 9357879 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 15
Study 8263570 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Quality of Life Questionnaire (GQLQ)
Number of subjects: 100
Study 8263570 — intervention group
Group type: COMPARATOR
Intervention: Rand Physical Function instrument
Number of subjects: 100
Study 8263570 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index
Number of subjects: 100
Study 8263570 — intervention group
Group type: EXPERIMENTAL
Intervention: GQLQ ADL domain
Number of subjects: 100
Study 8263570 — intervention group
Group type: EXPERIMENTAL
Intervention: GQLQ
Number of subjects: 100
Study 4030539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin alone
Number of subjects: 34
Study 4030539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin with aminoglycosides
Number of subjects: 34
Study 4030539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 34
Study 30545420 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention (MTG), 30-45 minutes weekly sessions, average of 7 sessions
Number of subjects: 21
Study 30545420 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), n=11
Number of subjects: 21
Study 27522631 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day spironolactone
Number of subjects: 360